In the News

FierceBiotech

August 20, 2018

Follow
Harbour BioMed
on WeChat

Back to list

FierceBiotech

August 20, 2018

Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China. Kelun stands to earn up to $350 million, but the partners did not specify how much the deal was worth upfront. 

Media Contact:

Harbour BioMed Public Relations

E-mail: pr@harbourbiomed.com